What Verdica's 799 score means for AJANTA PHARMA LTD
Ajanta Pharma Ltd received a composite score of 799 out of 850, placing it in the "strong" performance band (740–799). This score reflects consistent regulatory compliance across the three dimensions Verdica monitors: product approval, manufacturer profile integrity, and FDA compliance. A score in this range indicates that the provider meets established regulatory standards and maintains acceptable operational controls, though it does not reach the "excellent" threshold (800–850).
For a reader evaluating this provider, a 799 score signals that Ajanta Pharma has demonstrated reliable adherence to baseline requirements. However, the gap between 799 and 850 is notable—it suggests room for improvement or areas where performance does not yet reach the highest tier. Since no independent customer reviews are indexed, the assessment relies entirely on regulatory data sources: state board of pharmacy records, FDA compliance records, and DEA oversight. This means the score reflects regulatory bodies' findings rather than end-user experience.
How the sub-scores break down
Product Approval (850/850): This perfect sub-score indicates that Ajanta Pharma's products have passed regulatory approval pathways without flags. In the pharmacy and pharmaceutical manufacturing context, a maximal product approval score typically means the entity's portfolio has cleared required premarket review, meets identity and strength specifications, and carries no outstanding approval holds or suspensions. This is the strongest component of Ajanta Pharma's profile.
Manufacturer Profile (720/850): This sub-score is the lowest of the three and represents acceptable but not strong performance. Manufacturer profile assessments typically evaluate factors tracked by state boards of pharmacy and FDA: facility inspection outcomes, current good manufacturing practice (CGMP) compliance, record-keeping systems, and personnel qualifications. A score of 720 suggests Ajanta Pharma meets baseline expectations but may have received minor observations during inspections or has areas flagged for improvement—nothing severe enough to block operations, but notable enough to reduce the score below the strong band.
FDA Compliance (830/850): This strong sub-score reflects solid adherence to federal pharmaceutical regulations. FDA compliance tracking typically monitors warning letters, import alerts, product recalls, quality deviations, and adverse event reporting. A score of 830 indicates limited or no significant compliance violations and timely response to regulatory inquiries. The 20-point gap from perfect may reflect either a resolved historical issue or ongoing monitoring in a non-critical area.
What regulators track for pharmacy providers
Regulatory bodies maintain distinct oversight roles. State boards of pharmacy license facilities and personnel, verify continuing education, and investigate complaints and operational violations. They track unauthorized practice, dispensing errors, record falsification, and breach of patient confidentiality. FDA oversight focuses on manufacturing quality, product safety, and compliance with labeling and marketing standards. DEA monitoring centers on controlled substance handling, inventory controls, diversion prevention, and reporting accuracy.
Verdica's score incorporates data from these three sources. Infractions that would lower scores include manufacturing defects, regulatory warning letters, recall frequency, license suspensions or restrictions, failure to maintain required certifications, controlled substance discrepancies, or repeated inspection failures. Conversely, clean inspection histories, prompt responses to regulatory requests, documented quality improvements, and absence of recalls improve scores. The scoring model does not typically publish the specific threshold at which an individual violation moves the needle, but the principle is consistent: demonstrated compliance elevates scores, while violations lower them proportionally.
Bottom line
Ajanta Pharma Ltd's 799 score positions it as a strong, compliant provider suitable for business evaluation, though prospective partners should note that the manufacturer profile sub-score (720) is lower than the others. Anyone considering a relationship with Ajanta Pharma should independently verify current licensing status through relevant state pharmacy boards, review any publicly available FDA inspection reports, and confirm that products meet their specific quality and regulatory requirements.